An open-label ascending dose cohort study to assess the safety, pharmacokinetics, and preliminary efficacy of neoGAA (GZ402666) in patients with infantile-onset Pompe disease treated with alglucosidase alfa who demonstrate clinical decline
Clinical Trial Grant
Administered By
Pediatrics, Medical Genetics
Awarded By
Sanofi US
Start Date
May 14, 2018
End Date
December 31, 2022
Administered By
Pediatrics, Medical Genetics
Awarded By
Sanofi US
Start Date
May 14, 2018
End Date
December 31, 2022